PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Homologous recombination (HR) DNA repair defects are common in BRCA-mutated cancers.
• Poly(ADP-ribose) polymerase (PARP) inhibitors exploit these defects to induce synthetic lethality.
• PARP inhibitors are being explored beyond germline BRCA mutations due to somatic BRCA pathway deficiencies.

Purpose of the Study:

• To review the efficacy and tolerability of PARP inhibitors in ovarian cancer.
• To assess the activity of PARP inhibitors in both BRCA-deficient and sporadic tumors.
• To identify future directions for PARP inhibitor therapy in gynecologic malignancies.

Main Methods:

• Review of Phase I and II clinical trials involving PARP inhibitors.
• Analysis of treatment responses in epithelial ovarian, fallopian tube, and primary peritoneal cancers.
• Evaluation of patient populations including those with germline BRCA mutations and sporadic tumors.

Main Results:

• PARP inhibitors demonstrate significant activity in epithelial ovarian, fallopian tube, and primary peritoneal cancers.
• Responses are observed in both BRCA-deficient and BRCA-proficient (sporadic) tumors.
• Efficacy does not appear to be dependent on prior platinum sensitivity.

Conclusions:

• PARP inhibitors represent a viable therapeutic strategy for a broader range of ovarian cancers than initially anticipated.
• While well-tolerated as monotherapy, combination strategies require further investigation for optimal efficacy and safety.
• Continued research and community effort are crucial for advancing PARP inhibitor drug registration and clinical application.